Department of Critical Care Medicine, Cangzhou Central Hospital, Cangzhou, China.
Department of Pharmacology, Cangzhou Medical College, Cangzhou, China.
J Clin Lab Anal. 2022 Aug;36(8):e24569. doi: 10.1002/jcla.24569. Epub 2022 Jun 26.
Long noncoding RNA (lncRNA) cancer susceptibility candidate gene 2 (CASC2) inhibits inflammation and multi-organ dysfunction in various ways. The present study was intended to explore the potency of blood lncRNA CASC2 as a biomarker for sepsis management.
Totally, 184 sepsis patients and 30 healthy controls were enrolled. The reverse transcription-quantitative polymerase chain reaction was used to detect lncRNA CASC2 expression in peripheral blood mononuclear cell samples from the subjects. Mortality during 28 days was recorded in sepsis patients.
LncRNA CASC2 was decreased in sepsis patients [median (interquartile range [IQR]): 0.473 (0.241-0.773)] by comparison to healthy controls [median (IQR): 1.019 (0.676-1.685)] (p < 0.001). In sepsis patients, lncRNA CASC2 was negatively correlated with Acute Physiology and Chronic Health Evaluation II (APACHE II) (p = 0.001), Sequential Organ Failure Assessment (SOFA) (p < 0.001), SOFA-respiratory system (p = 0.010), SOFA-coagulation (p = 0.020), SOFA-liver (p = 0.019), and SOFA-renal (p = 0.010) scores, but was not related to SOFA-nervous (p = 0.466) and SOFA-cardio vascular system (p = 0.059) scores. Additionally, lncRNA CASC2 was negatively related to tumor necrosis factor-α (p = 0.024), interleukin (IL)-1β (p = 0.013), and IL-17A (p = 0.002), but was not linked to IL-6 (p = 0.112) or IL-10 (p = 0.074). Furthermore, lncRNA CASC2 was lower in sepsis deaths [median (IQR): 0.286 (0.166-0.475)] than in survivors [median (IQR): 0.534 (0.296-0.811)] (p < 0.001). Simultaneously, Kaplan-Meier (KM) curve analysis also observed that lncRNA CASC2 was inversely related to accumulating mortality in sepsis patients (p = 0.003). While lncRNA CASC2 could independently predict lower mortality risk.
Circulating lncRNA CASC2 inadequacy indicates the release of inflammatory cytokines, severe multi-organ injuries, and increased mortality in sepsis patients.
长链非编码 RNA(lncRNA)癌症易感性候选基因 2(CASC2)通过多种方式抑制炎症和多器官功能障碍。本研究旨在探讨血液 lncRNA CASC2 作为脓毒症管理生物标志物的潜力。
共纳入 184 例脓毒症患者和 30 名健康对照者。采用逆转录定量聚合酶链反应检测受试者外周血单个核细胞样本中 lncRNA CASC2 的表达。记录脓毒症患者 28 天内的死亡率。
与健康对照组[中位数(四分位距[IQR]):1.019(0.676-1.685)相比,脓毒症患者的 lncRNA CASC2 降低[中位数(IQR):0.473(0.241-0.773)](p<0.001)。在脓毒症患者中,lncRNA CASC2 与急性生理学和慢性健康评估 II(APACHE II)评分(p=0.001)、序贯器官衰竭评估(SOFA)评分(p<0.001)、SOFA-呼吸系统评分(p=0.010)、SOFA-凝血系统评分(p=0.020)、SOFA-肝脏评分(p=0.019)和 SOFA-肾脏评分(p=0.010)呈负相关,但与 SOFA-神经系统评分(p=0.466)和 SOFA-心血管系统评分(p=0.059)无相关性。此外,lncRNA CASC2 与肿瘤坏死因子-α(p=0.024)、白细胞介素(IL)-1β(p=0.013)和 IL-17A(p=0.002)呈负相关,但与 IL-6(p=0.112)或 IL-10(p=0.074)无关。此外,与存活者[中位数(IQR):0.534(0.296-0.811)相比,脓毒症死亡者的 lncRNA CASC2 水平更低[中位数(IQR):0.286(0.166-0.475)](p<0.001)。同时,Kaplan-Meier(KM)曲线分析还观察到,lncRNA CASC2 与脓毒症患者累积死亡率呈负相关(p=0.003)。而 lncRNA CASC2 可以独立预测较低的死亡率风险。
循环 lncRNA CASC2 不足表明炎症细胞因子释放、多器官严重损伤和脓毒症患者死亡率增加。